Lena MoranAdams - Telix Pharmaceuticals G Counsel

TLPPF Stock  USD 16.00  0.82  5.40%   

Insider

Lena MoranAdams is G Counsel of Telix Pharmaceuticals Limited
Phone61 3 3093 3897
Webhttps://telixpharma.com

Telix Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.4111) % which means that it has lost $0.4111 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.5507) %, meaning that it generated substantial loss on money invested by shareholders. Telix Pharmaceuticals' management efficiency ratios could be used to measure how well Telix Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Telix Pharmaceuticals Limited has accumulated 2.57 M in total debt with debt to equity ratio (D/E) of 0.02, which may suggest the company is not taking enough advantage from borrowing. Telix Pharmaceuticals has a current ratio of 3.15, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Telix Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Telix Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Telix Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Telix to invest in growth at high rates of return. When we think about Telix Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 9 records

INSIDER Age

Shachar CPAEnlivex Therapeutics
47
Sigal AradEnlivex Therapeutics
N/A
Simon BeaudoinDefence Therapeutics
39
Carrie CesaroneDefence Therapeutics
58
Eric TseSino Biopharmaceutical Ltd
27
Oren HershkovitzEnlivex Therapeutics
47
Pr MDEnlivex Therapeutics
68
Moutih RafeiDefence Therapeutics
41
Sebastien PlouffeDefence Therapeutics
51
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company was founded in 2015 and is headquartered in North Melbourne, Australia. Telix Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. Telix Pharmaceuticals Limited [TLPPF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Telix Pharmaceuticals Leadership Team

Elected by the shareholders, the Telix Pharmaceuticals' board of directors comprises two types of representatives: Telix Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Telix. The board's role is to monitor Telix Pharmaceuticals' management team and ensure that shareholders' interests are well served. Telix Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Telix Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Jyoti BappSc, Chief APAC
Meredith Crowe, Interim Culture
BSc BSc, Chief Scientist
Christian Davis, EMEA Marketing
Andreas MD, Chief Director
Amanda Griffin, Communications Mang
BEng DPhil, Group CoFounder
Kyahn Williamson, Sr Relations
BBus FCPA, Group Officer
Lena MoranAdams, G Counsel
AGIA ACG, Risk Governance

Telix Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Telix Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in Telix Pink Sheet

When determining whether Telix Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Telix Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Telix Pharmaceuticals Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Telix Pharmaceuticals Limited Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Please note, there is a significant difference between Telix Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Telix Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telix Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.